Improving intradermal dosing consistency in mice using a hollow microneedle: A model study with a SARS-CoV-2 mRNA vaccine

Intradermal vaccination can enhance immune responses, yet reproducible intradermal injection remains technically challenging, particularly for hollow microneedle delivery. Herein, using a mouse model, we aimed to establish a preclinical platform that enables more consistent intradermal vaccine delivery. We quantified age-dependent changes in mouse dorsal skin thickness and developed a pinch-type applicator, a hollow microneedle for mice, and an inserter to stabilize the skin and standardize effective skinfold thickness and insertion depth. Skinfold thickness measured using manual calipers varied with age, whereas cryosection-based measurements of the skin layer thickness from the outer surface to the dermal-subcutaneous adipose tissue interface showed only modest variations, indicating that visible age-related changes largely reflect skinfold structure. Skin-thickness-guided control of the pinching diameter markedly improved intradermal deliverability, and the feasibility of this process was confirmed in male C57BL/6J mice before vaccination. The mice were immunized twice at 2-week intervals with an mRNA-lipid nanoparticle (mRNA-LNP) vaccine encoding SARS-CoV-2 spike, delivered intramuscularly or intradermally at multiple dose levels; anti-receptor-binding domain (RBD) IgG responses measured at a fixed serum dilution and spike-specific cellular responses were evaluated 2 weeks post-boost. Intradermal administration induced measurable anti-RBD IgG responses and showed a tendency toward increased spike-specific cytokine-positive CD8a+ T cells compared with intramuscular dosing at the same dose, although this difference was not statistically significant. Collectively, this platform improved intradermal dosing consistency in mice and supported standard immunogenicity and immune-subset analyses, supporting incorporation of the intradermal route into small-animal proof-of-concept studies for the development of vaccines and therapeutics.

Authors

Institutions

Publication Details

Journal
Vaccine
Published
2026-09-05
DOI
https://doi.org/10.1016/j.vaccine.2026.129111
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Improving intradermal dosing consistency in mice using a hollow microneedle: A model study with a SARS-CoV-2 mRNA vaccine

Tomoya Nishimura, Natsumi Koike, Masaki Yamamoto, Takuya Mori et al.
Vaccine
Advancements in Transdermal Drug Delivery
article

Improving intradermal dosing consistency in mice using a hollow microneedle: A model study with a SARS-CoV-2 mRNA vaccine

Tomoya Nishimura, Natsumi Koike, Masaki Yamamoto, Takuya Mori, Koki Sugimoto, Takatoshi Niitsu, Takehiko Tojo, Atsuko Otsuka, Ryota Shiiba, Shintaro Onishi, Yuta Suzuki, Wataru Hariu
article en

Abstract

Intradermal vaccination can enhance immune responses, yet reproducible intradermal injection remains technically challenging, particularly for hollow microneedle delivery. Herein, using a mouse model, we aimed to establish a preclinical platform that enables more consistent intradermal vaccine delivery. We quantified age-dependent changes in mouse dorsal skin thickness and developed a pinch-type applicator, a hollow microneedle for mice, and an inserter to stabilize the skin and standardize effective skinfold thickness and insertion depth. Skinfold thickness measured using manual calipers varied with age, whereas cryosection-based measurements of the skin layer thickness from the outer surface to the dermal-subcutaneous adipose tissue interface showed only modest variations, indicating that visible age-related changes largely reflect skinfold structure. Skin-thickness-guided control of the pinching diameter markedly improved intradermal deliverability, and the feasibility of this process was confirmed in male C57BL/6J mice before vaccination. The mice were immunized twice at 2-week intervals with an mRNA-lipid nanoparticle (mRNA-LNP) vaccine encoding SARS-CoV-2 spike, delivered intramuscularly or intradermally at multiple dose levels; anti-receptor-binding domain (RBD) IgG responses measured at a fixed serum dilution and spike-specific cellular responses were evaluated 2 weeks post-boost. Intradermal administration induced measurable anti-RBD IgG responses and showed a tendency toward increased spike-specific cytokine-positive CD8a+ T cells compared with intramuscular dosing at the same dose, although this difference was not statistically significant. Collectively, this platform improved intradermal dosing consistency in mice and supported standard immunogenicity and immune-subset analyses, supporting incorporation of the intradermal route into small-animal proof-of-concept studies for the development of vaccines and therapeutics.

VaccineVol. 92
Kao Corporation (Japan) (JP)
Kao Corporation
Good health and well-being
Openalex Percentile: Top 12%
Advancements in Transdermal Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.